



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 38/39	A1	(11) International Publication Number: WO 97/48415 (43) International Publication Date: 24 December 1997 (24.12.97)
(21) International Application Number: PCT/US97/09689 (22) International Filing Date: 4 June 1997 (04.06.97) (30) Priority Data: 60/018,950 5 June 1996 (05.06.96) US (71) Applicants: THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02110 (US). SHI- SEIDO CO., LTD. [JP/JP]; 7-5-5, Ginza, Chuo-ku, Tokyo 104 (JP). (72) Inventors: BURGESSON, Robert, E.; 84 Naugus Avenue, Marblehead, MA 01945 (US). TSUNENAGA, Makoto; 129-B-208, Mamedo-cho, Kohoku-ku, Yokohama 222 (JP). AMANO, Satoshi; 1-36-1-1113, Izumihon-cho, Komae-shi, Tokyo 201 (JP). NISHIYAMA, Toshio; 2-22-2, Mis- uji, Taito-ku, Tokyo 111 (JP). ADACHI, Eijiro; 7-23- 8, Asamizodai, Sagami-hara-shi, Kanagawa 228 (JP). SH- IOYA, Nobuyuji; 241-5, Yamate-cho, Naka-ku, Yokohama- shi, Kanagawa 231 (JP). (74) Agents: MYERS, Paul, Louis et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: LAMININ-5 AND THE FORMATION OF BASEMENT MEMBRANE STRUCTURE		
(57) Abstract The use of laminin-5 to promote formation of basement membrane and to form skin equivalents and to improve grafting of keratinocyte sheets.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

LAMININ 5 AND THE FORMATION OF BASEMENT MEMBRANE STRUCTURE

BACKGROUND OF THE INVENTION

5 The invention relates to the use of laminin 5 to induce or promote the formation, e.g., the *in vivo* formation, of basement membrane.

SUMMARY OF THE INVENTION

10 In general, the invention features, a method of promoting the formation of a basement membrane, preferably a complete basement membrane, between a substrate and a subject cell, e.g., an epidermal cell, which subject cell is preferably adhered to the membrane. The method includes: administering laminin 5, preferably purified laminin-5, at an interface between the substrate and the subject cell, e.g., a cell which is adhered to the substrate, thereby promoting basement membrane formation. Preferably the
15 laminin-5 is administered in sufficient quantity and for a sufficient time to allow formation of a complete basement membrane or to substantially improve the morphology or frequency of the basement membrane over what would be present if exogenous laminin-5 was not administered.

20 In preferred embodiments: the subject cell is an epidermal cell, e.g., a keratinocyte; the subject cell is adhered to the membrane.

 In preferred embodiments, the cell is a cell in a sheet of cells, e.g., autologous or allogenic cells, e.g., cells which have been cultured *in vitro*.

 In preferred embodiments the laminin-5 is administered at initial level of at least 0.5, more preferably 1.0 2.0, 10.0, 50, 100, $\mu\text{g}/\text{cm}^2$ of substrate.

25 In preferred embodiments the level of laminin-5 administered is maintained for at least 1, 3, 5, 10, 15, or 30 days.

 In preferred embodiments the laminin-5 is administered subsequent to a previous administration wherein said previous administration promotes the adhesion of the cell to a substrate.

30 In preferred embodiments the substrate is an *in vitro* substrate, e.g., the surface of a device or surgical appliance, or is an *in vitro* substrate on which a skin product or skin substitute is cultured.

 In preferred embodiments the substrate is an *in vivo* substrate, e.g., a second cell, e.g., a mesenchymal cell.

35 In preferred embodiments the substrate is a wound surface, a burn surface, a corneal surface, a graft surface, a dermal surface, the surface of liver, pancreas, tooth or gum tissue.

In preferred embodiments the laminin-5 is administered after attachment of the subject cell to the substrate or to the basement membrane or nascent basement membrane.

5 In preferred embodiments repeated administrations of laminin-5 are administered.

In preferred embodiments sufficient laminin-5 is administered to increase the quality of the basement membrane substantially over what would be seen in the absence of exogenously applied laminin 5. In preferred embodiments the amount of laminin-5 administered is sufficient to increase the basement membrane morphology or frequency
10 score, as described herein, by at least 20, 50, 75, 100, 200, or 500%.

In another aspect, the invention features, a method of producing skin equivalents *in vitro*. The method includes: provided a contracted substrate; culturing cells, e.g., keratinocytes, on the substrate in the presence of exogenously added laminin-5 to thereby produce a skin equivalent.

15 In preferred embodiments the contracted substrate is, e.g., a fibroblast-contracted substrate, e.g., a e.g., a fibroblast-contracted gel substrate.

A purified preparation of a peptide or protein is a preparation which is substantially free of at least one of the peptides or proteins the subject molecule naturally occurs with in a cell. A purified preparation of a non-naturally occurring peptide is one
20 which is at least 10% by weight of the subject peptide or protein.

A complete basement membrane is one which includes one, two, three, or more of the following: a continuous lamina densa; a lamina lucida; hemidesmosomes which are normal or substantially normal in morphology, number, and distribution; and anchoring fibrils which are, normal or substantially normal in morphology, number, and
25 distribution.

The inventors have shown that the administration of exogenous laminin-5 can promote the formation of a complete and ultrastructurally normal basement membrane. The inventors have developed organotypic cultures of human keratinocytes and dermal fibroblasts for the production of skin equivalents. The keratinocytes can be grown upon
30 fibroblast-contracted collagen gels. In the culture, keratinocytes and fibroblasts derived from human neonatal or adult skin produce basement membrane components and these molecules are deposited at the interface of keratinocytes and collagen gels.

The methods of the invention can be used in promoting basement membrane formation, to establish the skin equivalents, and to elucidate the mechanism of
35 assembly for basement membrane zone. Laminin 5 was identified as the anchoring filament protein. To function as a bridge structure between the keratinocyte and the basement membrane, laminin 5 must interact with components of the basement

membrane and with its cell surface binding proteins. The effect of laminin 5 on the formation of basement membrane structure in the skin equivalents is described herein.

Other features and advantages of the invention will be apparent from the following description and from the claims.

5

Detailed Description

Drawings

The drawings are first briefly described.

Fig. 1 is a diagram of the dermo-epidermo junction model.

10

Fig. 2 is descriptions of the basement membrane scoring system used herein.

Fig. 3A (control) and 3B (laminin-5) are depictions of basement membrane structure.

Fig. 4A (control) and Fig. 4B (laminin 5) show the *in vivo* effect of laminin 5 on basement membrane formation.

15

In vitro skin equivalents

Skin equivalents (human foreskin keratinocytes and fibroblasts) were cultured for a week in standard culture medium for organotypic culture. The skin equivalents were cultured for an additional one week in the culture medium with (1) 5 µg/ml laminin 5. The medium was renewed every other day. After 2 weeks culture, the ultrastructure of the dermal-epidermal junction *in vitro* was determined by electronmicroscopy.

20

The recognizable structure of basement membrane (Fig. 1), such as lamina densa, lamina lucida, hemidesmosomes and anchoring fibrils, were detected, but only slightly, in the control culture (Fig. 3A). In contrast to the results with the control culture, recognizable and classic structures of the basement membrane, such as continuous lamina densa, lamina lucida, hemidesmosomes, were frequently detected in the skin equivalents cultured with laminin 5 (5 µg/ml) (Fig. 3B). Data from the first experiment, which were confirmed by determining scores of the basement membrane structure morphometrically, are indicated in Table 1 below.

25

30

TABLE 1

Score of basement membrane quality

	Control	Laminin-5
First Experiment	1.6	2.7
Second Experiment	4.7	8.8

35

The quality of the basement membrane formation was expressed by scores. The scores were calculated by determining the formation pattern as is shown in Fig. 2. The results indicate that laminin 5 promotes basement membrane formation. The frequency of the basement membrane structure on the culture with laminin 5 was higher than that of control. The effect of laminin 5 was reconfirmed in a second experiment.

While not wishing to be bound by theory, it is possible that laminin 5 added to the culture medium binds to its receptor in the keratinocyte plasma membrane and limits the diffusion of certain basement membrane components from keratinocytes and fibroblasts, and stabilizes the assembly of the molecules sufficiently so that ultrastructural formation of these molecules can occur.

In vivo Transplantation of Cultured Keratinocyte Sheets

Autologous transplantation of cultured human keratinocyte sheets has been used clinically for the treatment of extensive burns, giant nevus, and other disorders. In practice, the rate of take of the sheets transplanted directly to granulation tissue without dermal components has been less than optimal, . , other disorders are often wererculture areareThe inventors have shown that is and as such provide for improved metals of grafting. The inventors have discovered that can

The effect of laminin 5 upon the efficiency of transplantation of keratinocyte sheets to nude mice was followed in the following experiment. Keratinocyte sheets were prepared according to the method of Rheinwald and Green. In group 1 (laminin 5: mice n=12; rats n=15), purified laminin 5 was added to the sheets (1.0 µg/cm²). DMEM alone was added to group 2 (control: mice n=12; rats n=15). The sheets were grafted to the panniculus carnosus of nude mice (Balb/c nu/nu) (n=12) and to nude rats (Fisher 344) (n=15). The take rate was assessed by photometric measurement of the area of surviving epithelium at 7 days post grafting by NIH image analysis. Sections were prepared for examination by immuno-histochemistry and electron microscopy.

Laminin 5 bound the coated keratinocyte sheets. At 7 days post grafting, the area of epithelization of group 1 was significantly larger than that of group 2, as shown in Table 2,

The percentage of graft take of cultured human keratinocyte sheets

	pretreatment with laminin 5	control
nude mice (n=12)	58.5±21.9*	38.8 ±30.5
nude rats (n=15)	53.1 ± 20.9**	35.3 ±22.5

The values are the mean+ SD.

*,P<0.05. **,P<0.01.

Collage IV, laminin 5 and collagen VII stained more strongly (by immuno-chemical staining) at the dermal-epidermal junction in group 1 than in group 2. Integrin chains $\alpha 6$ and $\beta 4$ were similar in both groups. At day 3 after grafting the lamina densa of group 1 grafts were more continuous relative to group 2 when the well-grafting areas were examined as shown in Fig. 4. At day 7 after grafting, the basement membrane formation in group 1 is identical as compared to the control. When scored by the system of Fig. 2 the control was 3.9 and the laminin-5 trial was 20.3. Thus, pretreatment of cultured human keratinocyte sheets with laminin 5 improved the extent of epithelial coverage and increased the rate of neobasement membrane formation.

These experiments are described in more detail below.

Cultured epidermal sheets with laminin 5 were prepared as follows. Human skin keratinocytes were cultured using a 3T3 feeder layer in a keratinocytic growth medium which was prepared according to the method reported by Rheinwald and Green. The keratinocyte sheets were detached from dishes using dispase. The sheets were washed and then placed onto a aterocollagen sheet for the carrier. Purified laminin 5 in DMEM (1 μ g/ml) was added onto the sheets. After incubation the sheets were washed with Hank's solution.

Epidermal sheets were drafted as follows.

Skin flaps (1.5 cm square) of nude rats or nude mice were elevated and full thickness skin defects were made in the backs. The cultured epidermal sheets were grafted on the panniculus carnosus. Silicone gauze was applied over the sheets, then the skin flap was replaced on, and the margin was sutured. The take rate was assessed by photometric measurement of the area of existing the epidermal sheets 7 days after grafting. Mean values of the areas were analyzed by NIH image system.

Statistical analysis was performed as follows. All data were expressed as the mean and standard error (SEM). Comparison between means in each group were performed by t-test (Statview). Differences having a P value <0.05 were considered significant.

Histological examination and immunohistochemistry were performed as follows.

The skin pieces were fixed by AMeX method. Briefly, the pieces were incubated overnight in acetone at -20°C . The pieces were placed in acetone and incubated for 15 min at 4°C . and then for 15 min at RT. The pieces were incubated twice with methyl benzoate for 15 min at RT and twice with xylene for 15 min at RT. After the incubation with solvent, the skin pieces were incubated with paraffin for 3 hours at 60°C .

Paraffin sections were deparaffinized with xylene, immediately immersed twice in acetone, and washed with PBS, followed by immunostaining by using streptavidin-

biotinylated-peroxidase complex (SAB) method with monoclonal antibodies listed below.

	Laminin 5 (BM165)	2 µg/ml
	Collagen IV (JK199)	culture sup. (1:5)
5	Collagen VII (NP185)	6 µg/ml
	Integrin α6 (Chemicon Int. Co.)	1:100
	Integrin β4 (Chemicon Int. Co.)	1:100

The sections were incubated with 2%NSS (normal swine serum) for 20 min, then primary antibodies were added and incubated overnight at 4°C. The sections were rinsed with PBS and incubated with biotinylated anti-mouse IgG (1:200, Vector Lab. Inc.) for 1 hour at RT. They were incubated with SAB (1:100, Amersham) for 1 hour at RT. After rinsed with PBS, the sections were incubated in solution of DAB (diaminobenzodine) for 5 min. Nuclear counterstaining was performed with Carazzi hematoxylin solution.

15 Electronmicroscopy was performed as follows,

For electron microscopy, the grafted skins were excised with the surrounding tissue and fixed with 2% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4, then post fixed with 1% OsO₄ in 0.1 M cacodylate buffer, dehydrated through an ethanol series, and embedded in Quetol 812 (Nissin EM Co., Ltd., Japan). Ultra thin sections were prepared with an ultramicrotome (Portor-Blum MT-IIB or LKB NOVA), stained with uranyl acetate and lead citrate, and examined under a JEM-100SX or H-600 electron microscope.

as shown in Table 2

25

Other Embodiments

Laminin 5 is described in the invention also includes the use of any biologically active fragment or analog of a laminin-5 protein. By "biologically active" is meant possessing any *in vivo* or *in vitro* activity which is characteristic of laminin-5, e.g., laminin-5 activity as described above. A laminin-5 protein fragment or analog possesses, most preferably 90%, preferably 40%, or at least 10%, of the activity of a naturally occurring laminin-5 isoform in any *in vivo* or *in vitro* laminin-5 assay.

Preferred analogs include laminin-5 peptides or recombinant laminin-5 proteins or peptides (or biologically active fragments thereof) whose sequences differ from the wild-type sequence by one or more conservative amino acid substitutions or by one or more non-conservative amino acid substitutions, deletions, or insertions which do not abolish biological activity. Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics, e.g., substitutions within the

following groups: valine, glycine; glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Other conservative substitutions can be taken from the table below.

5

CONSERVATIVE AMINO ACID REPLACEMENTS

For Amino Acid	Code	Replace with any of
Alanine	A	D-Ala, Gly, beta-Ala, L-Cys, D-Cys
Arginine	R	D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg, Met, Ile, D-Met, D-Ile, Orn, D-Orn
Asparagine	N	D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln
Aspartic Acid	D	D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln
Cysteine	C	D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr
Glutamine	Q	D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp
Glutamic Acid	E	D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln
Glycine	G	Ala, D-Ala, Pro, D-Pro, β -Ala, Acp
Isoleucine	I	D-Ile, Val, D-Val, Leu, D-Leu, Met, D-Met
Leucine	L	D-Leu, Val, D-Val, Leu, D-Leu, Met, D-Met
Lysine	K	D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn
Methionine	M	D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val
Phenylalanine	F	D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4, or 5-phenylproline, cis-3,4, or 5-phenylproline
Proline	P	D-Pro, L-1-thioazolidine-4-carboxylic acid, D-or L-1-oxazolidine-4-carboxylic acid
Serine	S	D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O), L-Cys, D-Cys
Threonine	T	D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(O), D-Met(O), Val, D-Val
Tyrosine	Y	D-Tyr, Phe, D-Phe, L-Dopa, His, D-His
Valine	V	D-Val, Leu, D-Ile, Ile, D-Ile, Met, D-Met

Other useful modifications include those which increase peptide stability; such analogs may contain, for example, one or more non-peptide bonds (which replace peptide bonds) or D-amino acids in the peptide sequence.

10

Analogs can differ from a naturally occurring laminin-5 protein in amino acid sequence or can be modified in ways that do not affect sequence, or both. Analogs of the invention will generally exhibit at least 70%, more preferably 80%, more preferably 90%, and most preferably 95% or even, 99%, homology with a segment of 20 amino acid residues, preferably more than 40 amino acid residues or more preferably the entire sequence of naturally occurring laminin-5 protein sequence.

15

Alterations in primary sequence include genetic variations, both natural and induced. Also included are analogs that include residues other than naturally occurring L-amino acids, e.g., D-amino acids or non-naturally occurring or synthetic amino acids, e.g., β or γ amino acids. Alternatively, increased stability may be conferred by cyclizing the peptide molecule.

Nonsequence modification include *in vivo* or *in vitro* chemical derivatization or polypeptides, e.g., acetylation, methylation, phosphorylation, carboxylation, or glycosylation; glycosylation can be modified, e.g., by modifying the glycosylation patterns of a polypeptide during its synthesis and processing or in further processing steps, e.g., by exposing the polypeptide to glycosylation-affecting enzymes derived from cells that normally provide such processing, e.g., mammalian glycosylation enzymes; phosphorylation can be modified by exposing the polypeptide to phosphorylation-altering enzymes, e.g., kinases or phosphatases.

Other embodiments are within the following claims.

What is claimed is:

1. A method of promoting the formation of a basement membrane between a
5 substrate and a subject cell, which subject cell is adhered to the membrane comprising:
administering laminin 5, at an interface between the substrate and the subject cell,
thereby promoting basement membrane formation, and provided that the laminin-5 is
administered in sufficient quantity and for a sufficient time to: allow formation of a
complete basement membrane or to substantially improve the morphology or frequency
10 of the basement membrane over what would be present if exogenous laminin-5 was not
administered.
2. The method of claim 1, wherein is an epidermal cell
- 15 3. The method of claim 1, wherein said cell is a keratinocyte.
4. The method of claim 1, wherein said cell is in a sheet of cells.
5. The method of claim 4, wherein said cell is autologous cells which have been
20 cultured *in vitro*.
6. The method of claim 1, wherein said laminin-5 is administered at initial level
of at least 0.5 $\mu\text{g}/\text{cm}^2$ of substrate.
- 25 7. The method of claim 1, wherein the level of laminin-5 administered is is
maintained for at least 5 days.
8. The method of claim 1, wherein the amount of laminin-5 administered is
sufficient to increase the basement membrane morphology or frequency score, as
30 described herein, by at least 20%.
9. A method of producing skin equivalents *in vitro* comprising: provided a
fibroblast-contracted gel substrate; culturing cells on the substrate in the presence of
exogenously added laminin-5 to thereby produce a skin equivalent.
35
10. The method of claim 9, wherein the contracted substrate is a fibroblast-
contracted substrate.

11. The method of claim 9, wherein the substrate is a fibroblast-contracted gel substrate

5 12. The method of claim 9, wherein said laminin-5 is administered at initial level of at least $0.5 \mu\text{g}/\text{cm}^2$ of substrate.

10 13. The method of claim 9, wherein the level of laminin-5 administered is maintained for at least 5 days.

14. The method of claim 9, wherein the amount of laminin-5 administered is sufficient to increase the basement membrane morphology or frequency score, as described herein, by at least 20%.

15 15. A method of grafting cultured keratinocyte sheets in vivo comprising:
providing a keratinocyte sheet;
grafting said sheet on the panniculus carnosus in the presence of exogenously added laminin-5,
said laminin-5 being present at a concentration sufficient to improve the extent of
20 epithelial coverage and to promote formation of a complete basement membrane.

16. The method of claim 15, wherein said sheet comprises autologous cells.


25 17. The method of claim 15, wherein said sheet has been cultured *in vitro*.

18. The method of claim 15, wherein said laminin-5 is administered at initial level of at least $0.5 \mu\text{g}/\text{cm}^2$ of substrate.

30 19. The method of claim 15, wherein the level of laminin-5 administered is maintained for at least 5 days.

20. The method of claim 15, wherein the amount of laminin-5 administered is sufficient to increase the basement membrane morphology or frequency score, as
35 described herein, by at least 20%.

1/4



Dermo-epidermal junction model (X 100,000)

FIGURE 1.




FIGURE 2.

In vitro skin equivalents




Fig 3

BEST AVAILABLE COPY

In vivo transplantation of cultured keratinocyte sheets




Fig. 4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/09689**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61K 38/39

US CL : 514/12, 21; 530/356

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/12, 21; 530/356

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, E	US 5,660,982 A (TRYGGVASON et al.) 26 August 1997, see whole document.	1-20

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be of particular relevance	*X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	*Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means	
*P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 09 SEPTEMBER 1997	Date of mailing of the international search report 24.11.97
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer CHHAYA SAYALA
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/09689

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAS ONLINE, EMBASE, MEDLINE, BIOSIS, WPIDS

search terms: laminin-5, basement membrane, kalinin, epidermal, keratinocytes